Zydus Lifesciences Receives USFDA Approval for Generic Indocyanine Green Injection
Zydus Lifesciences has received final approval from the US Food and Drug Administration for its generic version of indocyanine green for injection, an optical imaging agent used in various surgical and diagnostic procedures. The USFDA designated the drug as a Competitive Generic Therapy, potentially granting Zydus 180 days of marketing exclusivity. The product will be manufactured at Zydus's USFDA-approved facility in Gujarat and marketed in the US through its subsidiary. The company highlighted the complexity and precision involved in developing this imaging agent.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 40/100.
Outlets measured: news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 4 Aug, 10:56 am. Other outlets followed.
- 1